Dexamethasone in Hospitalized Patients with Covid-19.

null nullPeter HorbyWei Shen LimJonathan R EmbersonMarion MafhamJennifer L BellLouise LinsellNatalie StaplinChristopher BrightlingAndrew UstianowskiEinas ElmahiBenjamin PrudonChristopher GreenTimothy FeltonDavid ChadwickKanchan RegeChristopher FeganLucy C ChappellSaul N FaustThomas JakiKatie JefferyAlan MontgomeryKathryn RowanEdmund JuszczakJ Kenneth BaillieRichard HaynesMartin J Landray

Published in: The New England journal of medicine (2020)

In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936; ISRCTN number, 50189673.).

Keyphrases

mechanical ventilation
acute respiratory distress syndrome
end stage renal disease
coronavirus disease
high dose
low dose
intensive care unit
newly diagnosed
sars cov
prognostic factors
cardiovascular events
risk factors
quality improvement
type diabetes
coronary artery disease
patient reported outcomes